Recombinant Full Length Milnesium Tardigradum Aquaporin-5(Aqp5) Protein, Tag-Free
| Cat.No. : | RFL29582MF |
| Product Overview : | Recombinant Full Length Milnesium tardigradum Aquaporin-5(AQP5) Protein (G5CTG2) (1-277aa) was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
| Source : | E.coli expression system |
| Species : | Milnesium tardigradum (Water bear) (Tardigrade) |
| Tag : | Tag-Free |
| Form : | Lyophilized powder |
| Protein length : | Full Length (1-277) |
| AA Sequence : | MWCFNPRSSIEDLAKIQFWKALGAE FIGTAVLVYIGCGAAVTSTPDANRD AFVTRVSLAFGLTVATMVWAICGVS GGHINPAVSLGFLVTRRISLVRFLL YVAFQCSGAVAGAALLYASTFDSVK RGGFGTNSMATENGQYLISPAQGIL IEAIITFVLVFTVFATCDAKRSDLK GSGPLAIGIAVLISHLVAIPLTGTS MNPARSLGPAVLIGFWTDHWVFWVG PMLGGAVAGLLYDMAFAADASLRKF GECAVADDYDPDADDRTIDTKRVNA RV Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request. |
| Purity : | Greater than 90% as determined by SDS-PAGE. |
| Applications : | SDS-PAGE |
| Notes : | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
| Storage : | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
| Storage Buffer : | Tris/PBS-based buffer, 6% Trehalose, pH 8.0 |
| Reconstitution : | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference. |
| Gene Name : | AQP5 |
| Synonyms : | AQP5Aquaporin-5; AQP-5 |
| UniProt ID : | G5CTG2 |
| Gene Name : | AQP5 |
| Synonyms : | AQP5Aquaporin-5; AQP-5 |
| UniProt ID : | G5CTG2 |
Products Types
| ◆ Recombinant Protein | ||
| AQP5-236H | Recombinant Human AQP5 Protein, His-tagged | +Inquiry |
| AQP5-650M | Recombinant Mouse AQP5 Protein, His (Fc)-Avi-tagged | +Inquiry |
| Aqp5-237M | Recombinant Mouse Aqp5 Protein, His&GST-tagged | +Inquiry |
| AQP5-395R | Recombinant Rat AQP5 Protein, His (Fc)-Avi-tagged | +Inquiry |
| AQP5-739R | Recombinant Rat AQP5 Protein | +Inquiry |
| ◆ Lysates | ||
| AQP5-33HCL | Recombinant Human AQP5 lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (26)
Ask a questionYes, various factors can influence the expression of AQP5 in the lungs. For example, growth factors like epidermal growth factor (EGF) and transforming growth factor-beta (TGF-beta) can stimulate AQP5 expression, while inflammatory mediators such as interferons and tumor necrosis factor alpha (TNF-alpha) can downregulate its expression.
Yes, various factors can influence the expression of AQP5 in the lungs. For example, growth factors like epidermal growth factor (EGF) and transforming growth factor-beta (TGF-beta) can stimulate AQP5 expression, while inflammatory mediators such as interferons and tumor necrosis factor alpha (TNF-alpha) can downregulate its expression.
The structure of AQP5 has been determined using techniques such as X-ray crystallography and cryo-electron microscopy. These methods provide detailed information about the arrangement of atoms and help understand how the protein functions as a water channel.
Yes, alterations in AQP5 expression or function have been associated with various diseases. For example, reduced levels of AQP5 have been observed in patients with Sjögren's syndrome, an autoimmune disorder that affects exocrine glands and causes dry mouth and dry eyes. AQP5 dysfunction has also been implicated in the development of respiratory disorders, including asthma and chronic obstructive pulmonary disease (COPD).
The modulation of AQP5 expression or activity has the potential for therapeutic benefits in various conditions. For example, in dry eye disease, increasing AQP5 expression or function in the lacrimal glands may help enhance tear production and alleviate symptoms. Similarly, targeting AQP5 in respiratory disorders or other fluid imbalance-related conditions could potentially improve lung function or restore fluid balance. However, more research is needed to fully understand the therapeutic potential and safety of such interventions.
The modulation of AQP5 expression or activity has the potential for therapeutic benefits in various conditions. For example, in dry eye disease, increasing AQP5 expression or function in the lacrimal glands may help enhance tear production and alleviate symptoms. Similarly, targeting AQP5 in respiratory disorders or other fluid imbalance-related conditions could potentially improve lung function or restore fluid balance. However, more research is needed to fully understand the therapeutic potential and safety of such interventions.
Yes, mutations in the AQP5 gene have been associated with certain human diseases. For instance, a mutation in the AQP5 gene has been linked to autosomal dominant diffuse non-epidermolytic palmoplantar keratoderma (AD-palmoplantar keratoderma), which is a skin disorder characterized by thickened skin on the palms and soles. Additionally, alterations in AQP5 expression or function have been implicated in conditions such as Sjögren's syndrome and chronic obstructive pulmonary disease (COPD).
Yes, mutations in the AQP5 gene have been associated with certain human diseases. For instance, a mutation in the AQP5 gene has been linked to autosomal dominant diffuse non-epidermolytic palmoplantar keratoderma (AD-palmoplantar keratoderma), which is a skin disorder characterized by thickened skin on the palms and soles. Additionally, alterations in AQP5 expression or function have been implicated in conditions such as Sjögren's syndrome and chronic obstructive pulmonary disease (COPD).
Yes, mutations in the AQP5 gene have been identified in some individuals with conditions like X-linked cataracts, which cause opacity in the lens of the eye, and nephrogenic diabetes insipidus, a disorder characterized by excessive thirst and urination.
Yes, ongoing research aims to better understand the role of AQP5 in various diseases and conditions, including respiratory disorders. Scientists are investigating ways to modulate its function pharmacologically, which may lead to the development of new treatment options for related conditions.
AQP5 is crucial for the secretion of saliva and tears. It is highly expressed in the acinar cells of salivary and lacrimal glands, where it facilitates the movement of water across the cell membranes. This allows for the production and secretion of saliva and tears, helping to maintain oral and ocular moisture.
AQP5 is crucial for the secretion of saliva and tears. It is highly expressed in the acinar cells of salivary and lacrimal glands, where it facilitates the movement of water across the cell membranes. This allows for the production and secretion of saliva and tears, helping to maintain oral and ocular moisture.
Currently, there are no approved drugs or therapies specifically targeting AQP5. However, there is ongoing research exploring the development of compounds that can modulate AQP5 expression or function. Some studies have shown promising results with experimental drugs in preclinical models of conditions such as dry eye disease and respiratory disorders. Nevertheless, further research and clinical trials are needed before any targeted AQP5 therapies can be widely used in clinical practice.
Currently, there are no approved drugs or therapies specifically targeting AQP5. However, there is ongoing research exploring the development of compounds that can modulate AQP5 expression or function. Some studies have shown promising results with experimental drugs in preclinical models of conditions such as dry eye disease and respiratory disorders. Nevertheless, further research and clinical trials are needed before any targeted AQP5 therapies can be widely used in clinical practice.
Yes, AQP5 expression can be regulated by hormones. For example, studies have shown that the hormone estrogen can upregulate AQP5 expression in the lacrimal glands and salivary glands. Additionally, thyroid hormones have also been found to influence AQP5 expression in the lungs and other tissues.
Yes, AQP5 expression can be regulated by hormones. For example, studies have shown that the hormone estrogen can upregulate AQP5 expression in the lacrimal glands and salivary glands. Additionally, thyroid hormones have also been found to influence AQP5 expression in the lungs and other tissues.
Currently, there are no approved drugs that specifically target AQP5. However, ongoing research aims to identify and develop compounds that can modulate AQP5 activity, which may have potential therapeutic applications in diseases where abnormal fluid transport occurs.
The expression of AQP5 can be regulated by various factors, including hormones, growth factors, and cellular signaling pathways. For example, the production of saliva and tears can stimulate AQP5 expression, while certain disease conditions or medications can decrease its expression.
Yes, given its involvement in various diseases, AQP5 is being explored as a potential therapeutic target. Modulating AQP5 function could potentially help manage conditions related to fluid secretion and absorption, such as dry mouth and dry eye symptoms in Sjögren's syndrome.
Targeting AQP5 for therapeutic interventions is an area of active research. Modulating its expression, activity, or regulation may have potential applications in conditions related to fluid imbalance, such as dry eye disease, Sjögren's syndrome, and certain respiratory disorders. However, further studies are needed to fully understand the implications and develop targeted therapies.
Targeting AQP5 for therapeutic interventions is an area of active research. Modulating its expression, activity, or regulation may have potential applications in conditions related to fluid imbalance, such as dry eye disease, Sjögren's syndrome, and certain respiratory disorders. However, further studies are needed to fully understand the implications and develop targeted therapies.
Yes, there is a connection between AQP5 and dry eye disease. Dry eye disease is characterized by a reduction in tear production and/or increased tear evaporation, leading to ocular dryness and discomfort. Studies have shown that decreased expression or dysfunction of AQP5 in the lacrimal glands can contribute to the development of dry eye disease.
Yes, there is a connection between AQP5 and dry eye disease. Dry eye disease is characterized by a reduction in tear production and/or increased tear evaporation, leading to ocular dryness and discomfort. Studies have shown that decreased expression or dysfunction of AQP5 in the lacrimal glands can contribute to the development of dry eye disease.
Besides its role as a water channel, AQP5 has been suggested to have additional functions. It has been implicated in cell migration and tissue inflammation, although the precise mechanisms are still being investigated. Further research is needed to fully understand these additional functions of AQP5.
Besides its role as a water channel, AQP5 has been suggested to have additional functions. It has been implicated in cell migration and tissue inflammation, although the precise mechanisms are still being investigated. Further research is needed to fully understand these additional functions of AQP5.
Yes, the altered expression or function of AQP5 has been suggested as a potential biomarker in certain diseases. For instance, decreased levels of AQP5 in saliva samples may serve as a biomarker for Sjögren's syndrome, aiding in its diagnosis.
Customer Reviews (8)
Write a reviewIn addition to their expertise, the manufacturer's technical support team can assist in troubleshooting and optimizing the handling and application of the AQP5 protein.
the AQP5 protein's high quality and its compatibility with my experimental needs, coupled with the manufacturer's excellent technical support, create a valuable alliance that contributes to successful research endeavors.
This level of support ensures that researchers have a seamless experience, enabling them to focus on their research goals without worrying about logistical or technical concerns.
researchers highly appreciate AQP5 protein for its excellent performance in ELISA assays and protein electron microscopy structure analysis.
The manufacturer's commitment to providing high-quality proteins is evident in their meticulous production process, ensuring the purity and reliability of the ARAE protein.
They offer comprehensive technical support, including responsive customer service, availability of product information, and timely delivery of the product.
AQP5 protein offers numerous advantages in trials, ranging from its stability and bioactivity to the manufacturer's commitment to customer support.
The AQP5 protein is characterized by its exceptional quality, making it an ideal choice to fulfill my experimental requirements.
Ask a Question for All AQP5 Products
Required fields are marked with *
My Review for All AQP5 Products
Required fields are marked with *
Inquiry Basket
